# 2026年3月1日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 醋酸艾司利卡西平用于具有卒中后癫痫高风险的卒中患者预防癫痫发作的安全性与有效性：一项概念验证、2a 期、随机、双盲、安慰剂对照的抗癫痫发生试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722592)
**期刊：** The Lancet. Neurology
**PMID：** 41722592
**DOI：** 10.1016/S1474-4422(25)00491-0

### 第一部分 原文与翻译

**英文原标题：** Safety and efficacy of eslicarbazepine acetate for seizure prevention in patients with stroke at high risk of developing post-stroke epilepsy: a proof-of-concept, phase 2a, randomised, double-blind, placebo-controlled antiepileptogenesis trial.

> **英文摘要：**
> BACKGROUND: Eslicarbazepine acetate is an antiseizure medication that has shown potential antiepileptogenic effects in preclinical models of epilepsy. We aimed to investigate whether eslicarbazepine acetate could prevent or reduce the incidence of unprovoked seizures after acute ischaemic stroke or acute intracerebral haemorrhage.
> 
> METHODS: Study BIA-2093-213 was an exploratory, proof-of-concept, phase 2a, double-blind, randomised, placebo-controlled trial conducted in adults (aged ≥18 years) after an acute ischaemic stroke or acute intracerebral haemorrhage, who were considered at high risk of developing unprovoked seizures based on a severity of stroke, large artery atherosclerosis, early seizure, cortical involvement, and territory of the middle cerebral artery (SeLECT) score of 5 or greater or a cortical involvement of intracerebral haemorrhage, age, volume, and early seizure after intracerebral haemorrhage (CAVE) score of 2 or greater. Patients were recruited from 19 university hospitals across Austria, Germany, Italy, Israel, Portugal, Spain, Sweden, and the UK, and eligible for inclusion if randomisation was planned within 96 h since the known time of stroke, or last time seen well (prolonged to 120 h to allow detection of acute seizures within 5 days post-stroke following a protocol modification implemented early in recruitment). Participants were randomly assigned (1:1) to receive eslicarbazepine acetate 800 mg/day or placebo, administered orally, for 30 days and followed up for 17 additional months. All patients who received one dose of study drug were included in safety and efficacy analyses. The primary endpoint was the proportion of patients who had a first unprovoked seizure, died, or discontinued (for any reason) within the first 6 months after randomisation. This trial is registered on the EudraCT database (EudraCT 2018-002747-29).
> 
> FINDINGS: Between May 29, 2019, and Feb 28, 2022, 129 patients were screened and 125 were randomly assigned (62 to eslicarbazepine acetate and 63 to placebo). The between-group difference for the primary endpoint (17 [28%] of 61 with eslicarbazepine acetate vs 23 [37%] of 62 with placebo) was not significant (odds ratio 0·66 [95% CI 0·31-1·40]; p=0·37). Treatment-emergent adverse events were reported with similar frequency in both eslicarbazepine acetate and placebo groups (50 [82%] of 61 vs 51 [82%] of 62). The most common treatment-emergent adverse events were hyponatraemia (five [8%] of 61 in the eslicarbazepine acetate group vs one [2%] of 62 in the placebo group), dizziness (three [5%] vs none). Serious treatment-emergent adverse events were reported in 12 (20%) patients in the eslicarbazepine acetate group and 13 (21%) in the placebo group. Three serious related treatment-emergent adverse events occurred in the eslicarbazepine acetate group (none in the placebo group): nodal arrhythmia, hepatic failure, and hyponatraemia (one patient each). Five patients died after randomisation (all in the eslicarbazepine acetate group), but deaths were deemed unrelated or unlikely to be related to the study drug.
> 
> INTERPRETATION: The proportion of patients who had a first unprovoked seizure, died, or discontinued at 6 months did not differ significantly between the eslicarbazepine acetate and placebo groups. However, the trial was underpowered owing to slow recruitment and the COVID-19 pandemic, producing wide confidence intervals. The findings indicate that antiepileptogenesis studies are feasible, and guide the design of adequately powered trials with clinically meaningful endpoints.
> 
> FUNDING: BIAL.

> **中文摘要：**
> 背景：醋酸艾司利卡西平是一种抗癫痫药物，在癫痫前期模型中已显示出潜在的抗癫痫发生作用。本研究旨在探讨醋酸艾司利卡西平是否能预防或降低急性缺血性卒中或急性脑出血后非诱发性癫痫的发作。
> 
> 方法：BIA-2093-213 研究是一项探索性、概念验证、2a 期、双盲、随机、安慰剂对照试验，在发生急性缺血性卒中或急性脑出血的成人（年龄≥18岁）中进行。根据卒中严重程度、大动脉粥样硬化、早期癫痫、皮层受累和大脑中动脉供血区（SeLECT）评分等于或大于 5 分，或脑出血皮层受累、年龄、出血量和早期癫痫（CAVE）评分等于或大于 2 分，这些患者被认为具有发生非诱发性癫痫的高风险。患者从奥地利、德国、意大利、以色列、葡萄牙、西班牙、瑞典和英国的 19 家大学医院招募。如果计划在卒中已知时间或最后一次见好的时间后的 96 小时内（在招募早期实施的方案修改后延长至 120 小时，以允许检测卒中后 5 天内的急性癫痫发作）进行随机化，则符合入选条件。参与者被随机分配（1:1）接受每日 800 毫克的口服醋酸艾司利卡西平或安慰剂，持续 30 天，并随访 17 个月。所有接受过一剂研究药物的患者均被纳入安全性和有效性分析。主要终点是随机化后前 6 个月内发生首次非诱发性癫痫、死亡或（因任何原因）治疗中断的患者比例。该试验已在 EudraCT 数据库注册（EudraCT 2018-002747-29）。
> 
> 结果：在 2019 年 5 月 29 日至 2022 年 2 月 28 日期间，筛选了 129 例患者，125 例被随机分配（62 例分配至醋酸艾司利卡西平组，63 例分配至安慰剂组）。主要终点的组间差异（醋酸艾司利卡西平组 61 例中有 17 例 [28%]，而安慰剂组 62 例中有 23 例 [37%]）不显著（优势比 0.66 [95% CI 0.31-1.40]；p=0.37）。醋酸艾司利卡西平组和安慰剂组报告的治疗期间出现的不良事件（TEAE）频率相似（61 例中有 50 例 [82%] 对比 62 例中有 51 例 [82%]）。最常见的 TEAE 为低钠血症（醋酸艾司利卡西平组 61 例中有 5 例 [8%]，安慰剂组 62 例中有 1 例 [2%]）和头晕（3 例 [5%] 对比 0 例）。醋酸艾司利卡西平组有 12 例（20%）患者报告了严重 TEAE，安慰剂组有 13 例（21%）。醋酸艾司利卡西平组发生了三例严重的相关 TEAE（安慰剂组无）：结性心律失常、肝衰竭和低钠血症（各一例）。随机化后有五例患者死亡（均在醋酸艾司利卡西平组），但这些死亡被认为与研究药物无关或不太可能相关。
> 
> 结论：6 个月时发生首次非诱发性癫痫、死亡或中断治疗的患者比例在醋酸艾司利卡西平组和安慰剂组之间无显著差异。然而，由于招募缓慢和 COVID-19 大流行，该试验的效力不足，导致置信区间较宽。研究结果表明，抗癫痫发生研究是可行的，并为设计具有足够效力和临床意义终点的试验提供了指导。

### 第二部分 AI 大师评价

本研究是一项针对卒中后癫痫预防（抗癫痫发生）的创新性探索。研究通过 SeLECT 和 CAVE 评分精准筛选高风险受试者，虽然由于样本量受限和疫情干扰导致主要终点未达统计学显著差异，但其试验设计的严谨性和可行性为该领域后续临床试验奠定了基础。值得注意的是，醋酸艾司利卡西平组出现的低钠血症等严重不良事件及死亡病例（尽管判定不相关）提示了在该类高龄卒中人群中用药的安全性挑战。

---

## 2. Fordadistrogene movaparvovec 在杜氏肌营养不良症门诊患者中的安全性和有效性（CIFFREO）：一项 3 期、双盲、随机、安慰剂对照研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722591)
**期刊：** The Lancet. Neurology
**PMID：** 41722591
**DOI：** 10.1016/S1474-4422(26)00036-0

### 第一部分 原文与翻译

**英文原标题：** Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.

> **英文摘要：**
> BACKGROUND: Gene transfer is a promising therapeutic approach for Duchenne muscular dystrophy as the disease results from mutations in a single gene. Fordadistrogene movaparvovec is an investigational recombinant adeno-associated virus 9 (rAAV9)-based vector encoding a mini-dystrophin transgene protein for Duchenne muscular dystrophy . We aimed to assess the safety and efficacy of fordadistrogene movaparvovec in slowing the functional decline experienced by individuals with Duchenne muscular dystrophy.
> 
> METHODS: CIFFREO was a phase 3, double-blind, randomised, placebo-controlled study done at 45 academic and hospital sites in Australia, Belgium, Canada, France, Germany, Israel, Italy, Japan, Russia, South Korea, Spain, Switzerland, Taiwan, the UK, and the USA. Eligible participants were male, ambulatory, aged 4 years to younger than 8 years, with a genetic diagnosis of Duchenne muscular dystrophy. Participants were randomly assigned (2:1) using interactive response technology, stratified by age (<6 years or ≥6 years), to cohort 1 (intravenous fordadistrogene movaparvovec 2 × 10 vector genomes [vg]/kg on day 1, placebo on day 390) or cohort 2 (placebo on day 1, intravenous fordadistrogene movaparvovec 2 × 10 vg/kg on day 390). Placebo vials were provided and prepared identically to fordadistrogene movaparvovec. Participants, investigators, and outcome assessors were masked to treatment assignments. The primary endpoint was change from baseline to week 52 in the North Star Ambulatory Assessment (NSAA) total score, assessed in patients in the full analysis set (all participants who were randomly assigned and received a single dose of fordadistrogene movaparvovec or placebo on day 1, excluding siblings and those meeting genetic exclusion criteria), analysed using a mixed model for repeated measures. Participants were analysed according the cohort to which they were assigned and analysis only included participants who completed the 1-year follow-up. The safety analysis set comprised all participants who were randomly assigned and received a single dose of fordadistrogene movaparvovec or placebo on day 1. The trial was registered at ClinicalTrials.gov (NCT04281485) and is active, not recruiting.
> 
> FINDINGS: Between Nov 5, 2020, and April 20, 2023, 226 participants were screened for eligibility, 122 of whom were randomly assigned (81 to cohort 1 and 41 to cohort 2). The primary outcome was analysed in 64 participants in the fordadistrogene movaparvovec group and 28 in the placebo group. At screening, mean age was 6·3 years (SD 1·3) in participants in the fordadistrogene movaparvovec group and 6·5 years (1·2) in participants in the placebo group; mean NSAA total score was 22·5 (SD 3·6) in the fordadistrogene movaparvovec group and 23·5 (3·9) in the placebo group. At week 52, the least squares mean change from baseline in NSAA total score was 1·46 (SE 0·43) for fordadistrogene movaparvovec and 1·37 (0·65) for placebo (difference between groups 0·09 [95% CI -1·46 to 1·64]; p=0·91). Adverse events occurred in 78 (99%) of 79 participants in the fordadistrogene movaparvovec group versus 27 (77%) of 35 in the placebo group. The most common adverse events in the fordadistrogene movaparvovec group versus the placebo group were vomiting (60 [76%] vs five [14%]), pyrexia (49 [62%] vs three [9%]), decreased appetite (26 [33%] vs one [3%]), nausea (23 [29%] vs three [9%]), increased liver glutamate dehydrogenase (19 [24%] vs zero), nasopharyngitis (19 [24%] vs six [17%]), and abdominal pain (17 [22%] vs three [9%]). Serious adverse events occurred in 25 (32%) participants in the fordadistrogene movaparvovec group versus five (14%) in the placebo group. There were no deaths in the study.
> 
> INTERPRETATION: The study did not meet its primary efficacy endpoint. Based on the efficacy and safety data from this phase 3 study, the benefit-risk profile of fordadistrogene movaparvovec was determined to be negative. Thus, the study sponsor has discontinued any further clinical development of this investigational gene therapy agent.
> 
> FUNDING: Pfizer.

> **中文摘要：**
> 背景：由于杜氏肌营养不良症（DMD）是由单一基因突变引起的，基因转移是一种极具前景的治疗方法。Fordadistrogene movaparvovec 是一种在研的基于重组腺相关病毒 9 (rAAV9) 的载体，编码用于治疗 DMD 的微型抗肌萎缩蛋白转基因。我们旨在评估 fordadistrogene movaparvovec 在减缓 DMD 患者功能衰退方面的安全性和有效性。方法：CIFFREO 是一项 3 期、双盲、随机、安慰剂对照研究，在澳大利亚、比利时、加拿大、法国、德国、以色列、意大利、日本、俄罗斯、韩国、西班牙、瑞士、台湾、英国和美国的 45 个学术和医院站点进行。合资格的参与者为男性、可行走、年龄在 4 岁至 8 岁以下，且有 DMD 的基因诊断。参与者被随机分配（2:1），按年龄分层，进入队列 1（第 1 天静脉注射 fordadistrogene movaparvovec 2 × 10¹⁴ vg/kg，第 390 天注射安慰剂）或队列 2（第 1 天注射安慰剂，第 390 天静脉注射 fordadistrogene movaparvovec 2 × 10¹⁴ vg/kg）。主要终点是 North Star 门诊评估 (NSAA) 总分从基线到第 52 周的变化，在全分析集中进行评估。结果：在 122 名被随机分配的参与者中，主要结局分析涵盖了基因治疗组 64 人和安慰剂组 28 人。第 52 周时，基因治疗组 NSAA 总分较基线的最小二乘平均变化为 1.46，安慰剂组为 1.37（组间差异 0.09 [95% CI -1.46 至 1.64]；p=0.91）。基因治疗组中 99% 的参与者发生不良事件，而安慰剂组为 77%。严重不良事件在基因治疗组发生率为 32%，而安慰剂组为 14%。研究中无死亡病例。解释：该研究未达到其主要疗效终点。基于本项 3 期研究的疗效和安全性数据，fordadistrogene movaparvovec 的获益-风险剖面被判定为负面。因此，研究赞助商已停止该在研基因治疗药物的所有进一步临床开发。资助：辉瑞。

### 第二部分 AI 大师评价

本项 CIFFREO 研究是基因疗法治疗杜氏肌营养不良症（DMD）领域的一项重要挫折。尽管该疗法利用 rAAV9 载体递送微型抗肌萎缩蛋白，但在关键的 3 期临床试验中，主要疗效终点 NSAA 评分的改善与安慰剂相比并无显著统计学差异。此外，由于治疗组出现了显著高于对照组的不良事件及严重不良事件，其获益-风险评估最终为负面。该结果不仅直接导致了该药物研发的中止，也凸显了高剂量系统性 AAV 基因疗法在实现临床有效性与安全性平衡方面所面临的巨大挑战。

---

## 3. 迈向卒中后癫痫抗癫痫发生疗法的一步

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722577)
**期刊：** The Lancet. Neurology
**PMID：** 41722577
**DOI：** 10.1016/S1474-4422(26)00039-6

### 第一部分 原文与翻译

**英文原标题：** A step towards antiepileptogenic therapies for post-stroke epilepsy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文探讨了卒中后癫痫（PSE）防治领域的核心挑战，重点关注从传统的抗发作药物向干预癫痫发生过程的“抗癫痫发生”疗法转变。尽管目前临床尚无公认的预防手段，但该文指出了针对卒中后级联反应进行早期干预的潜在可能性。其核心价值在于为改善卒中幸存者的长期神经系统预后提供了新的研究方向与治疗思路。

---

## 4. 阿尔茨海默病中的癫痫活动：新进展与治疗启示

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41581519)
**期刊：** The Lancet. Neurology
**PMID：** 41581519
**DOI：** 10.1016/S1474-4422(25)00425-9

### 第一部分 原文与翻译

**英文原标题：** Epileptic activity in Alzheimer's disease: emerging insights and therapeutic implications.

> **英文摘要：**
> An estimated 60% of patients with Alzheimer's disease develop epilepsy or subclinical epileptiform activity over the course of the disease. New-onset seizures in cognitively healthy adults also increase the risk of developing dementia. Epileptic activity, including both seizures and subclinical epileptiform discharges, can hasten the onset of Alzheimer's disease and accelerate cognitive decline. Studies are investigating whether antiseizure medications could improve cognitive outcomes, particularly in patients with Alzheimer's disease with epileptic activity. Detection of epileptic activity in people with Alzheimer's disease requires high clinical vigilance and neurophysiological monitoring. Evaluation and treatment of late-onset epilepsy or Alzheimer's disease-associated epileptic activity should be informed by clinical advances. Epilepsy management is especially important in patients receiving anti-amyloid monoclonal antibodies, which can increase seizure risk. Recent insights support the concept of an epileptic subtype of Alzheimer's disease, position epileptic activity as a modifiable risk factor in Alzheimer's disease, highlight innovations for earlier identification of epileptic activity, and provide evidence supporting the need for early detection and targeted treatment across the stages of Alzheimer's disease.

> **中文摘要：**
> 估计在阿尔茨海默病病程中，有60%的患者会出现癫痫或亚临床癫痫样活动。认知健康的成人新发癫痫也会增加患痴呆的风险。癫痫活动，包括癫痫发作和亚临床癫痫样放电，可加速阿尔茨海默病的发病并加快认知功能的下降。相关研究正在探讨抗癫痫药物是否能改善认知结果，特别是针对伴有癫痫活动的阿尔茨海默病患者。在阿尔茨海默病患者中检测癫痫活动需要高度的临床警惕和神经生理监测。晚发性癫痫或阿尔茨海默病相关癫痫活动的评估与治疗应基于最新的临床进展。对于接受抗淀粉样蛋白单克隆抗体治疗的患者，癫痫管理尤为重要，因为此类药物可能增加癫痫发作风险。近期的研究进展支持阿尔茨海默病“癫痫亚型”的概念，将癫痫活动定位为阿尔茨海默病的一个可干预风险因素，强调了早期识别癫痫活动的技术创新，并为在阿尔茨海默病各阶段进行早期检测和针对性治疗的需求提供了证据。

### 第二部分 AI 大师评价

本文系统阐述了阿尔茨海默病（AD）与癫痫活动之间紧密的病理联系，指出癫痫活动不仅是AD的高发并发症，更是加速认知衰退的可干预风险因素。文章特别强调了在新型抗淀粉样蛋白疗法背景下癫痫管理的重要性，并提出了AD“癫痫亚型”的前沿观点。通过整合临床进展与神经生理监测手段，本文为AD的早期预警、精准分型及靶向治疗提供了重要的理论支撑。

---

## 5. 在急诊科预测脑室分流管失效：SMaRT（分流管故障及修订分诊）评分

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41429286)
**期刊：** The Journal of pediatrics
**PMID：** 41429286
**DOI：** 10.1016/j.jpeds.2025.114969

### 第一部分 原文与翻译

**英文原标题：** Predicting Failure of Ventricular Shunts in the Emergency Department: The SMaRT (Shunt Malfunction and Revision Triage) Score.

> **英文摘要：**
> OBJECTIVE: To create a simple scoring system to stratify likelihood of shunt failure in the emergency department. STUDY DESIGN: We conducted a retrospective cohort study of all children presenting to the pediatric emergency department with concern for ventricular shunt failure from 2017 to 2022. A separate dataset from 2022 to 2023 was used for validation. The main predictors of shunt revision were determined using univariate and multivariable regression models, and a scoring system utilizing the top predictors of ventricular shunt malfunction was created. RESULTS: There were 1167 neurosurgical consultations for shunt malfunction during the study period which resulted in 285 shunt revisions. Utilizing the 10 variables most associated with revision (increased ventricle size, abnormal shunt series, bradycardia, lethargy, altered mental status, vomiting, headache, shorter time interval from last shunt surgery, seizure, and the presence of upper respiratory symptoms), a SMaRT score was developed. For Shunt Malfunction and Revision Triage (SMaRT) score <4, we achieved a receiver-operating characteristic area under the curve of 0.87 with sensitivity of 0.93, specificity of 0.58, positive predictive value of 0.42, and negative predictive value of 0.96. This was confirmed in a separate validation set of 119 patients. A similar analysis excluding imaging data yielded a significant decrease in the discrimination of the scoring system, dropping the receiver-operating characteristic area under the curve to 0.71. CONCLUSIONS: The SMaRT score provides a data-driven tool to determine the utility of a neurosurgical consult for shunt malfunction with a high negative predictive value for shunt malfunction in its lowest tier. Use of this tool has the potential to improve triage and resource utilization in the emergency department.

> **中文摘要：**
> 目的：建立一个简单的评分系统，用于在急诊科对脑室分流管失效的可能性进行风险分层。
> 研究设计：我们对2017年至2022年期间因怀疑脑室分流管失效而在小儿急诊科就诊的所有儿童进行了一项回顾性队列研究。使用2022年至2023年的独立数据集进行验证。通过单变量和多变量回归模型确定分流管修订的主要预测因素，并建立了一个利用脑室分流管故障核心预测因素的评分系统。
> 结果：研究期间共有1167次针对分流管故障的神经外科会诊，最终导致了285例分流管修订。利用与修订最相关的10个变量（脑室增大、分流管系列造影异常、心动过缓、嗜睡、意识状态改变、呕吐、头痛、距上次分流手术的时间间隔较短、癫痫发作以及存在上呼吸道症状），开发了SMaRT评分。对于分流管故障及修订分诊（SMaRT）评分<4分的情况，我们获得的受试者工作特征曲线下面积（AUC）为0.87，灵敏度为0.93，特异度为0.58，阳性预测值为0.42，阴性预测值为0.96。这在由119名患者组成的独立验证集中得到了证实。排除影像学数据的类似分析导致评分系统的区分度显著下降，AUC降至0.71。
> 结论：SMaRT评分提供了一个数据驱动的工具，用于确定分流管故障进行神经外科会诊的实用价值，且在其最低评分分层对排除分流管故障具有较高的阴性预测值。使用该工具具有改善急诊科分诊效率和资源利用率的潜力。

### 第二部分 AI 大师评价

该研究成功开发并验证了SMaRT评分系统，旨在解决儿科急诊中脑室分流管故障诊断的临床难题。通过整合临床体征与影像学特征，该评分系统在低分值区间展现出极高的阴性预测值（0.96），能有效识别低风险患儿以减少不必要的神经外科会诊和资源消耗。研究明确了影像学指标在预测模型中的核心地位，尽管受限于回顾性设计，但其为急诊分诊流程的标准化和医疗资源优化提供了强有力的证据支持。

---

## 6. 磁共振成像揭示脑缺血在婴幼儿受虐性脑损伤不同严重程度中的重要作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41271012)
**期刊：** The Journal of pediatrics
**PMID：** 41271012
**DOI：** 10.1016/j.jpeds.2025.114901

### 第一部分 原文与翻译

**英文原标题：** Magnetic Resonance Imaging Reveals an Important Role for Brain Ischemia Across Injury Severity in Abusive Head Trauma in Infants and Young Children.

> **英文摘要：**
> OBJECTIVE: To determine the prevalence and associations of ischemia with injury severity and discharge outcomes in pediatric traumatic brain injury (TBI). STUDY DESIGN: All imaging interpretations (head computed tomography [CT] and brain magnetic resonance imaging [MRI]) during hospitalization were reviewed in a retrospective cohort of children aged < 3 years admitted with TBI to our pediatric intensive care unit from 2011-2024. Initial TBI severity was defined by presenting Glasgow Coma Scale score as mild 13-15, moderate 9-12, or severe 3-8. Impairment was defined as an increase in Functional Status Score > 1 (preinjury to discharge). Data analysis used nonparametric tests. RESULTS: Of 946 children, 560/946 (59%) had only head CT, 52/946 (5%) had only brain MRI, and 334/946 (35%) had both. Ischemia was identified in 107/946 (14%) children (95 by MRI and 12 by CT) with 56 (52%) and 13 (12%) children with severe and moderate TBI, respectively. In mild TBI, ischemia was present in 35/232 (15%) cases of abusive head trauma (AHT) vs only 3/479 (0.3%) children with accidental TBI (P < .001). Children with ischemia had more impairment at discharge (80/107 [75%] vs 121/839 [14%], P < .001). CONCLUSIONS: Ischemia was associated with AHT and unfavorable outcomes. Ischemia in mild AHT suggests an unrecognized injury. Further work is needed to determine whether early MRI may be an important tool to detect ischemia and AHT.

> **中文摘要：**
> 目的：探讨儿科创伤性脑损伤（TBI）中脑缺血的患病率及其与损伤严重程度和出院结局的相关性。研究设计：本研究是一项回顾性队列研究，分析了2011年至2024年间因TBI入住我院儿科重症监护室的3岁以下儿童。研究回顾了患儿住院期间的所有影像学解读资料（头部计算机断层扫描[CT]和脑部磁共振成像[MRI]）。初始TBI严重程度根据就诊时的格拉斯哥昏迷评分（GCS）定义为：轻度13-15分，中度9-12分，或重度3-8分。功能障碍定义为功能状态评分（FSS）增加大于1分（从伤前至出院）。数据分析采用非参数检验。结果：在946名儿童中，560/946（59%）仅接受了头部CT检查，52/946（5%）仅接受了脑部MRI检查，334/946（35%）两者均接受了检查。在107/946（14%）名儿童中发现了脑缺血（其中95例经MRI检出，12例经CT检出），在重度和中度TBI患儿中分别有56例（52%）和13例（12%）出现缺血。在轻度TBI中，受虐性脑损伤（AHT）病例的缺血发生率为35/232（15%），而意外TBI儿童仅为3/479（0.3%）（P < .001）。伴有缺血的儿童在出院时存在更多功能障碍（80/107 [75%] 对比 121/839 [14%]，P < .001）。结论：脑缺血与AHT及不良结局相关。轻度AHT中出现的脑缺血提示存在未被识别的损伤。需要进一步研究来确定早期MRI是否可作为检测脑缺血和AHT的重要工具。

### 第二部分 AI 大师评价

本研究通过一项大型回顾性队列分析，突出了脑缺血在婴幼儿受虐性脑损伤（AHT）病理生理过程中的关键地位，特别是在临床表现为轻度损伤的病例中。研究揭示了MRI在检出脑缺血方面远优于常规CT，且缺血灶的存在与出院时的不良功能结局显著相关。其临床创新性在于量化了轻度AHT中隐匿性缺血的高发生率，为临床医生提供了加强早期MRI筛查以识别隐匿性颅脑损伤及区分受虐性与意外创伤的实证支持。

---

速递结束，祝您工作愉快！